Procyon Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.16M Sell
17,103
-18,948
-53% -$2.5M 0.09% 182
2026
Q1
$5.02M Buy
36,051
+7,656
+27% +$1.07M 0.25% 101
2025
Q4
$3.49M Sell
28,395
-1,809
-6% -$220K 0.17% 122
2025
Q3
$3.35M Buy
30,204
+3,721
+14% +$423K 0.2% 96
2025
Q2
$2.94M Buy
26,483
+3,536
+15% +$376K 0.28% 75
2025
Q1
$2.57M Sell
22,947
-11,367
-33% -$1.17M 0.16% 142
2024
Q4
$3.17M Sell
34,314
-1,930
-5% -$174K 0.2% 107
2024
Q3
$3.04M Buy
36,244
+3,214
+10% +$245K 0.21% 110
2024
Q2
$2.27M Sell
33,030
-1,202
-4% -$80.2K 0.17% 136
2024
Q1
$2.51M Buy
34,232
+3,955
+13% +$304K 0.19% 124
2023
Q4
$2.45M Buy
30,277
+1,263
+4% +$98.3K 0.21% 116
2023
Q3
$2.17M Buy
29,014
+11,688
+67% +$899K 0.22% 112
2023
Q2
$1.34M Buy
17,326
+7,246
+72% +$578K 0.17% 138
2023
Q1
$836K Sell
10,080
-5,979
-37% -$495K 0.14% 148
2022
Q4
$1.38M Sell
16,059
-1,983
-11% -$157K 0.25% 93
2022
Q3
$1.11M Buy
18,042
+1,087
+6% +$68.5K 0.27% 84
2022
Q2
$1.05M Sell
16,955
-1,000
-6% -$61.9K 0.23% 98
2022
Q1
$1.07M Sell
17,955
-4,980
-22% -$318K 0.22% 98
2021
Q4
$1.67M Buy
22,935
+1,209
+6% +$83.3K 0.36% 65
2021
Q3
$1.52M Buy
21,726
+8,130
+60% +$571K 0.39% 60
2021
Q2
$936K Buy
+13,596
New +$908K 0.26% 86
2020
Q4
Sell
-3,324
Closed -$210K 238
2020
Q3
$210K Sell
3,324
-161
-5% -$11.2K 0.12% 194
2020
Q2
$268K Buy
3,485
+1,132
+48% +$86.8K 0.14% 142
2020
Q1
$176K Buy
2,353
+182
+8% +$12.6K 0.12% 169
2019
Q4
$141K Buy
+2,171
New +$141K 0.09% 217

Other funds holding GILD

Procyon Advisors's GILD Position: Q2 2026 in Review

Procyon Advisors reduced its Gilead Sciences (GILD) stake by 53% in Q2 2026, selling an estimated $2.5M and leaving 17,103 shares worth $2.16M. The position accounts for 0.09% of the portfolio, ranked #182.

Procyon Advisors first reported a position in GILD in Q4 2019 and has held it in 25 quarters since. The position peaked at $5.02M in Q1 2026. 911 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Procyon Advisors held 17,103 shares of Gilead Sciences worth $2.16M as of Q2 2026.
  • Procyon Advisors sold 18,948 Gilead Sciences shares in Q2 2026, an estimated $2.5M.
  • Gilead Sciences made up 0.09% of Procyon Advisors's portfolio in Q2 2026, its #182 holding.
  • Procyon Advisors first reported a position in Gilead Sciences in Q4 2019 and has held it in 25 quarters since.
  • Procyon Advisors's Gilead Sciences position peaked at $5.02M in Q1 2026.
  • 911 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Procyon Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.